18F-deoxyglucose (FDG) PET-CMD

Nantes University Hospital (NUH)

Status

Completed

Conditions

Patients With Idiopathic Dilated Cardiomyopathy

Treatments

Drug: 18F-deoxyglucose (FDG)

Study type

Interventional

Funder types

Other

Identifiers

NCT02078141

RC14_0002

Details and patient eligibility

About

18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) may have application in a promising tool for identification of myocardial inflammation in patients with dilated cardiomyopathy (DCM).Therefore, the purpose of the study is to confirm the hypothesis of the fixation of FDG in non cardiomyocyte cells in a number of patients with DCM, to specify the frequency and describe the different binding profiles in comparison with MRI data.

Patients will perform an ethologic evaluation of a non ischemic DCM with in a cardiac MRI.

All patients will have with in 4 weeks after the MRI a 18F-fluorodeoxyglucose (FDG) PET. A high fat and low carbohydrate diet and an heparin injection will be prescribed to patients before this FDG PET.

Patients will be identified as FDG+ or FDG -. The clinical status of the patient will be completed by a 12 months evaluation.

Enrollment

30 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients above 18 years of age
Patients with DCM as defined by the European Society of Cardiology and recognized as such by the clinician cardiologist
DCM diagnosed for more than two weeks without new ventricular arrhythmias or AuriculoVentricular Block (AVB) second or third degree , who responded to the usual treatment in the first two weeks of treatment
No family history of DCM
Lake of clinical or biological cases for periphiral myopathy or myotonia
Absence of other causes of non-family DCM discovered during the initial etiological ( some deficiency , toxic alcoholic or drug )
Patients who underwent cardiac MRI for etiological DCM for less than four weeks at the time of obtaining consent
Patients who have read and understood the information letter and who signed the consent form
Affiliated to a social insurance

Exclusion criteria

Ischemic cardiomyopathy defined by history of myocardial infarction or myocardial revascularization , stenosis ≥ 75% of the core or the left coronary artery anterior interventricular proximal stenosis ≥ 75% on at least two epicardial vessels
Significant organic valvular echocardiography
Eosinophilia or immuno- allergic mechanism suspected
History of acute myocarditis
History of sarcoidosis
Family history of DCM
History of chemotherapy with anthracyclines
Patient with signs of circulatory failure or congestive heart failure requiring intravenous positive inotropic therapy or diuretic therapy
Treatment immunosuppressive received from cardiac MRI
Hypersensitivity to heparin.
History of severe thrombocytopenia type II ( heparin induced thrombocytopenia or immuno- allergic thrombocytopenia ) , heparin or unfractionated heparin , low molecular weight
Other causes of non-family DCM discovered during the initial etiological ( some deficiency , toxic alcohol or medication , endocrine )
Patients with active neoplasia
Patients with chronic liver disease
Patients with connective : rheumatoid arthritis , systemic lupus erythematosus , systemic sclerosis , dermato- polymyositis , mixed connective
Patients with Crohn's disease
Patients with active tuberculosis
Pregnant or lactating women
Minors
Major Trust
No affiliation to a social insurance